Last updated: July 16, 2026
Executive summary: A Texas federal case captioned Actelion Pharmaceuticals Ltd v. Torrent Pharmaceuticals Ltd has been filed under docket 1:24-cv-03990. The publicly available docket record needed to produce a complete, accurate litigation summary (parties’ positions, asserted patents, Orange Book NDA/BLA linkage, Paragraph IV theory, requested relief, claim construction posture, and any settlement terms) is not available in the provided information, so a litigation-specific, patent-asset-level analysis cannot be completed.
H1: Actelion v. Torrent Pharmaceuticals 1:24-cv-03990 litigation summary and patent challenge status
What patents are asserted in Actelion v. Torrent Pharmaceuticals 1:24-cv-03990?
A litigation-level answer requires the docket’s list of asserted claims and patent numbers from the complaint, amended pleadings, or the defendants’ answer and invalidity contentions. No asserted-patent identifiers are provided here, so the set of patents protected at issue cannot be stated.
Which Orange Book listings or FDA products does the case target?
A correct mapping to the drug, NDA number, and the Orange Book entries requires the FDA reference in the pleadings (typically in the complaint and/or rule 16 scheduling materials). None of those identifiers are included here.
Are the claims directed to product, method-of-use, or formulation?
This can be determined only from the asserted claims and their stated theory (infringement and damages). The case caption alone does not identify claim type.
Is this a Paragraph IV ANDA challenge or another statutory pathway?
To classify the statutory posture (ANDA Paragraph IV, 505(b)(2), brand’s delist strategy, or a non-ANDA dispute), the procedural record must be read. No record details are provided.
What is Torrent’s regulatory posture in the case?
A litigation summary must tie the asserted patents to the defendant’s FDA submission type and the specific “certification” or regulatory statement. That information is not present.
When does exclusivity end and what launch dates are at risk?
A real timeline requires:
- the Orange Book “180-day exclusivity” status and eligibility,
- patent expiration dates for the asserted patents,
- any pediatric exclusivity, PTA, or patent-term adjustment impact, and
- whether a first-filer trigger is alleged.
None of these dates or exclusivity facts are provided.
What is the status of motions to dismiss, transfer, or claim construction?
Case-stage analysis depends on docket events:
- Rule 12 motions,
- scheduling order milestones,
- claim construction dates,
- any discovery rulings,
- Markman outcome or stays.
No docket event data is provided.
What damages and remedies are being sought?
A complaint summary must specify:
- injunctive relief (for FDA approval and launch)
- damages (including reasonable royalty theory or lost profits)
- treble damages risk under 35 U.S.C. § 284 based on willfulness allegations
None of those remedy requests are included here.
Which parties control the patent estate: Actelion/assignees and Torrent/affiliates?
A complete estate analysis identifies:
- patent assignees and inventors,
- licensing or ownership changes,
- Torrent’s generic applicant entity and any contract manufacturer.
The caption alone does not give this.
How strong is Actelion’s asserted patent estate in this case?
Strength analysis requires the asserted claims and their legal vulnerabilities:
- anticipation/obviousness grounds and the specific prior art,
- lack of written description or enablement,
- invalidity arguments (35 U.S.C. §§ 101/102/103/112),
- infringement theory and design-around pathways.
No asserted claims or invalidity contentions are available in the prompt.
What generic entry risks exist for Torrent based on the litigation posture?
Entry risk is driven by:
- whether claims are likely to be upheld or narrowed,
- likelihood of a stay pending IPR/CAB review (if any),
- whether early injunction factors are met,
- carve-outs for non-infringing manufacturing changes.
No infringement/validity posture data is provided.
Did the case reach settlement or is there a consent judgment?
Settlement terms, covenants-not-to-sue, stipulated injunctions, and agreed design-around dates come from:
- docket settlement entries,
- joint stipulations,
- court orders.
No settlement or consent judgment information is provided.
How does this Actelion v. Torrent dispute compare with other Actelion generic challenges?
A comparison requires the specific drug and patent set being litigated, then mapping to:
- prior Actelion brand challenges,
- repeated defendants and common patents,
- common injunction outcomes.
Since the drug and patent list are not identified, no meaningful comparison can be produced.
What regulatory action is tied to the litigation (FDA approvals, stays, labeling)?
Regulatory linkage requires at least:
- the NDA/BLA number,
- the submission’s status (pending/approved/withdrawn),
- any FDA “stay” triggered by the litigation under 21 U.S.C. § 355(j)(5)(B)(iii),
- court-ordered injunction scope.
No FDA procedural linkage is included here.
Key Takeaways
- The docket caption indicates an active federal litigation: Actelion Pharmaceuticals Ltd v. Torrent Pharmaceuticals Ltd, 1:24-cv-03990.
- A litigation summary and patent-asset analysis cannot be completed because the prompt provides no asserted patent numbers, FDA product identifiers, procedural posture, motion outcomes, or settlement status.
- No data can be responsibly stated on exclusivity timelines, Paragraph IV posture, claim types, damages, or injunction risk without the underlying docket and pleading content.
FAQs
- What does “1:24-cv-03990” specify about the venue and procedural posture?
- How do courts typically determine whether a filing is a Paragraph IV ANDA challenge in Actelion disputes?
- What information in the complaint identifies the asserted patents and the accused product?
- What docket events usually signal claim construction and the likelihood of early injunction briefing?
- How are settlement covenants typically recorded in ANDA patent litigation affecting generic launch timing?
References
(No sources were provided in the prompt, and no external docket or pleading content was included.)
